Cyclin-Dependent Kinase Inhibitor AT7519 as a Potential Drug for MYCN-Dependent Neuroblastoma

Clinical Cancer Research

Volumn 21, Issue 22, 2015, Pages 5100-5109

  Dolman, M Emmy M ^a   Poon, Evon ^b   Ebus, Marli E ^a   Den Hartog, Ilona J M ^a   Van Noesel, Carel J M ^a   Jamin, Yann ^b   Hallsworth, Albert ^b   Robinson, Simon P ^b   Petrie, Kevin ^b   Sparidans, Rolf W ^c   Kok, Robbert J ^d   Versteeg, Rogier ^a   Caron, Huib N ^a   Chesler, Louis ^b   Molenaar, Jan J ^a  

^a UNIVERSITY OF AMSTERDAM   (Netherlands)

^b INSTITUTE OF CANCER RESEARCH   (United Kingdom)

^c UTRECHT UNIVERSITY   (Netherlands)

^d UTRECHT UNIVERSITY   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; AT 7519; CISPLATIN; CYCLIN DEPENDENT KINASE 2; CYCLIN DEPENDENT KINASE INHIBITOR; DOXORUBICIN; ETOPOSIDE; IRINOTECAN; NUCLEOPHOSMIN; RETINOBLASTOMA PROTEIN; TEMOZOLOMIDE; TOPOTECAN; UNCLASSIFIED DRUG; VINCRISTINE; 4-(2,6-DICHLOROBENZOYLAMINO)-1H-PYRAZOLE-3-CARBOXYLIC ACID PIPERIDIN-4-YLAMIDE; CDK2 PROTEIN, HUMAN; MYCN PROTEIN, HUMAN; N MYC PROTO ONCOGENE PROTEIN; NUCLEAR PROTEIN; ONCOPROTEIN; PIPERIDINE DERIVATIVE; PROTEIN KINASE INHIBITOR; PYRAZOLE DERIVATIVE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; AREA UNDER THE CURVE; ARTICLE; CANCER INHIBITION; CANCER REGRESSION; CANCER SURVIVAL; CELL VIABILITY; CONCENTRATION RESPONSE; CONTROLLED STUDY; DOSE RESPONSE; DRUG EFFICACY; DRUG EXPOSURE; DRUG TUMOR LEVEL; FEMALE; GENE; GENE AMPLIFICATION; HIGH RISK PATIENT; HUMAN; HUMAN CELL; IC50; IN VITRO STUDY; IN VIVO STUDY; MAXIMUM PLASMA CONCENTRATION; MOUSE; MYCN DEPENDENT NEUROBLASTOMA; MYCN GENE; NEUROBLASTOMA; NEUROBLASTOMA CELL LINE; NONHUMAN; PRIORITY JOURNAL; PROTEIN PHOSPHORYLATION; TIME TO MAXIMUM PLASMA CONCENTRATION; TRANSGENIC MOUSE; TUMOR VOLUME; TUMOR XENOGRAFT; ANIMAL; BIOSYNTHESIS; CELL PROLIFERATION; DRUG EFFECTS; DRUG SCREENING; GENE EXPRESSION REGULATION; GENETICS; PATHOLOGY; TUMOR CELL LINE;

ANIMALS; APOPTOSIS; CELL LINE, TUMOR; CELL PROLIFERATION; CYCLIN-DEPENDENT KINASE 2; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; MICE; N-MYC PROTO-ONCOGENE PROTEIN; NEUROBLASTOMA; NUCLEAR PROTEINS; ONCOGENE PROTEINS; PIPERIDINES; PROTEIN KINASE INHIBITORS; PYRAZOLES; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84943642374     PISSN: 10780432     EISSN: 15573265     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-15-0313     Document Type: Article

References (32)

1. Valentijn LJ, Koster J, Haneveld F, Aissa RA, van Sluis P, Broekmans ME, et al. Functional MYCN signature predicts outcome of neuroblastoma irrespective of MYCN amplification. Proc Natl Acad Sci U S A 2012;109: 19190-5.
2. Chan DA, Giaccia AJ. Harnessing synthetic lethal interactions in anticancer drug discovery. Nat Rev Drug Discov 2011;10:351-64.
3. KaelinWGJr. The concept of synthetic lethality in the context of anticancer therapy. Nat Rev Cancer 2005;5:689-98.
4. Fong PC, Boss DS, Yap TA, Tutt A, Wu P, Mergui-Roelvink M, et al. Inhibition of poly(ADP-ribose) polymerase in tumors from BRCA mutation carriers. N Engl J Med 2009;361:123-34.
5. Murga M, Campaner S, Lopez-Contreras AJ, Toledo LI, Soria R, Montana MF, et al. Exploiting oncogene-induced replicative stress for the selective killing of Myc-driven tumors. Nat Struct Mol Biol 2011;18:1331-5.
6. Cole KA, Huggins J, Laquaglia M, Hulderman CE, Russell MR, Bosse K, et al. RNAi screen of the protein kinome identifies checkpoint kinase 1 (CHK1) as a therapeutic target in neuroblastoma. Proc Natl Acad Sci U S A 2011; 108:3336-41.
7. Toyoshima M,Howie HL, Imakura M, Walsh RM, Annis JE, Chang AN, et al. Functional genomics identifies therapeutic targets for MYC-driven cancer. Proc Natl Acad Sci U S A 2012;109:9545-50.
8. Yang D, Liu H, Goga A, Kim S, Yuneva M, Bishop JM. Therapeutic potential of a synthetic lethal interaction between the MYC proto-oncogene and inhibition of aurora-B kinase. Proc Natl Acad Sci U S A 2010;107: 13836-41.
9. Molenaar JJ, Ebus ME, Geerts D, Koster J, Lamers F, Valentijn LJ, et al. Inactivation of CDK2 is synthetically lethal to MYCN over-expressing cancer cells. Proc Natl Acad Sci U S A 2009;106:12968-73.
10. Sallam H, El-Serafi I, Meijer L, Hassan M. Pharmacokinetics and biodistribution of the cyclin-dependent kinase inhibitor-CR8-in mice. BMC Pharmacol Toxicol 2013;14:50.
11. Nutley BP, Raynaud FI, Wilson SC, Fischer PM, Hayes A, Goddard PM, et al. Metabolism and pharmacokinetics of the cyclin-dependent kinase inhibitor R-roscovitine in the mouse. Mol Cancer Ther 2005;4:125-39.
12. Misra RN, Xiao HY, Kim KS, Lu S, Han WC, Barbosa SA, et al. N-(cycloalkylamino) acyl-2-aminothiazole inhibitors of cyclin-dependent kinase 2. N-[5-[[[5-(1,1-dimethylethyl)-2-oxazolyl]methyl]thio]-2-thiazolyl]-4-piperidinecarboxamide (BMS-387032), a highly efficacious and selective antitumor agent. J Med Chem 2004;47:1719-28.
13. Wyatt PG, Woodhead AJ, Berdini V, Boulstridge JA, Carr MG, Cross DM, et al. Identification of N-(4-piperidinyl)-4-(2,6-dichlorobenzoylamino)-1H-pyrazole-3-carboxamide (AT7519), a novel cyclin dependent kinase inhibitor using fragment-based X-ray crystallography and structure based drug design. J Med Chem 2008;51:4986-99.
14. Bate-Eya LT, Ebus ME, Koster J, den Hartog IJ, Zwijnenburg DA, Schild L, et al. Newly-derived neuroblastoma cell lines propagated in serum-free media recapitulate the genotype and phenotype of primary neuroblastoma tumours. Eur J Cancer 2014;50:628-37.
15. Lamers F, Schild L, Koster J, Versteeg R, Caron HN, Molenaar JJ. Targeted BIRC5 silencing using YM155 causes cell death in neuroblastoma cells with low ABCB1 expression. Eur J Cancer 2012;48:763-71.
16. Twentyman PR, Luscombe M. A study of some variables in a tetrazolium dye (MTT) based assay for cell growth and chemosensitivity. Br J Cancer 1987;56:279-85.
17. Workman P, Aboagye EO, Balkwill F, Balmain A, Bruder G, Chaplin DJ, et al. Guidelines for the welfare and use of animals in cancer research. Br J Cancer 2010;102:1555-77.
18. Kilkenny C, Browne WJ, Cuthill IC, Emerson M, Altman DG. Improving bioscience research reporting: The ARRIVE guidelines for reporting animal research. PLoS Biol 2010;8:e1000412.
19. Weiss WA, Aldape K, Mohapatra G, Feuerstein BG, Bishop JM. Targeted expression of MYCN causes neuroblastoma in transgenic mice. EMBO J 1997;16:2985-95.
20. Dolman MEM, den Hartog IJM, Molenaar JJ, Schellens JHM, Beijnen JH, Sparidans RW. Liquid chromatography-tandem mass spectrometric assay for the cyclin-dependent kinase inhibitor AT7519 in mouse plasma. J Pharm Biomed Anal 2014;88:216-20.
21. Squires MS, Feltell RE, Wallis NG, Lewis EJ, Smith DM, Cross DM, et al. Biological characterization of AT7519, a small-molecule inhibitor of cyclin-dependent kinases, in human tumor cell lines. Mol Cancer Ther 2009;8:324-32.
22. Mahadevan D, Plummer R, Squires MS, RensvoldD, Kurtin S, Pretzinger C, et al. A phase I pharmacokinetic and pharmacodynamic study of AT7519, a cyclin-dependent kinase inhibitor in patients with refractory solid tumors. Ann Oncol 2011;22:2137-43.
23. Delehouze C, Godl K, Loaec N, Bruyere C, Desban N, Oumata N, et al. CDK/CK1 inhibitors roscovitine and CR8 downregulate amplified MYCN in neuroblastoma cells. Oncogene 2014;33:5675-87.
24. Quarta C, Cantelli E, Nanni C, Ambrosini V, D'Ambrosio D, Di Leo K, et al. Molecular imaging of neuroblastoma progression in Th-MYCN transgenic mice. Mol Imaging Biol 2013;15:194-202.
25. Teitz T, Stanke JJ, Federico S, Bradley CL, Brennan R, Zhang J, et al. Preclinical models for neuroblastoma: Establishing a baseline for treatment. PLoS ONE 2011;6:e19133.
26. Chanthery YH, Gustafson WC, Itsara M, Persson A, Hackett CS, Grimmer M, et al. Paracrine signaling through MYCN enhances tumor-vascular interactions in neuroblastoma. Sci Transl Med 2012; 4:115ra3.
27. Jamin Y, Tucker ER, Poon E, Popov S, Vaughan L, Boult JK, et al. Evaluation of clinically translatableMRimaging biomarkers of therapeutic response in the TH-MYCN transgenic mouse model of neuroblastoma. Radiology 2013;266:130-40.
28. Calero R, Morchon E, Johnsen JI, Serrano R. Sunitinib suppress neuroblastoma growth through degradation of MYCN and inhibition of angiogenesis. PLoS ONE 2014;9:e95628.
29. Jamin Y, Glass L, Hallsworth A, George R, Koh DM, Pearson AD, et al. Intrinsic susceptibility MRI identifies tumors with ALKF1174L mutation in genetically-engineered murine models of high-risk neuroblastoma. PLoS ONE 2014;9:e92886.
30. Schell RF, Sidone BJ, Caron WP, Walsh MD, White TF, Zamboni BA, et al. Meta-analysis of inter-patient pharmacokinetic variability of liposomal and non-liposomal anticancer agents. Nanomedicine 2014; 10:109-17.
31. Squires MS, Cooke L, Lock V, Qi W, Lewis EJ, Thompson NT, et al. AT7519, a cyclin-dependent kinase inhibitor, exerts its effects by transcriptional inhibition in leukemia cell lines and patient samples. Mol Cancer Ther 2010;9:920-8.
32. Chen EX, Hotte S, Hirte H, Siu LL, Lyons J, Squires M, et al. A Phase I study of cyclin-dependent kinase inhibitor,AT7519, inpatientswith advanced cancer: NCIC Clinical Trials Group IND 177. Br J Cancer 2014;111:2262-7.